United States: Apotex Follows The Pre-Suit Information Exchange Provisions Of The BPCIA

Last Updated: September 13 2015
Article by Irena Royzman

In the first skirmishes between biosimilar makers and innovator companies, biosimilar makers attempted to bypass the litigation provisions of the Biologics Price Competition and Innovation Act of 2009 (BPCIA) through the filing of declaratory judgment actions, or by not participating in all or a subset of the BPCIA's pre-suit information exchanges (also known as the "patent dance"). Apotex, the third biosimilar maker to file an application for approval of a biosimilar product with FDA, chose a different path. As Amgen's recent lawsuit against Apotex reveals, Apotex is the first biosimilar applicant to participate in and complete the carefully orchestrated pre-suit information exchanges of the BPCIA.

Last year, Apotex submitted an application for a biosimilar version of Amgen's Neulasta (pegfilgrastim), a blockbuster drug used to prevent infections in cancer patients. Amgen's Neulasta is an improved long-lasting version of Amgen's Neupogen that was approved by FDA in 2002. Neulasta consists of Neupogen with a covalently bound polyethylene glycol (PEG) molecule that allows Neulasta to be administered less frequently than Neupogen.

After the FDA accepted Apotex's biosimilar application for review in December 2014, Apotex proceeded to follow the information exchange provisions of the BPCIA. As described in Amgen's complaint, Apotex provided Amgen a copy of its abbreviated Biologics License Application (aBLA) within twenty days of its aBLA being accepted for review. 42 U.S.C. § 262(l)(2)(A). On February 27, 2015, within 60 days of receiving the aBLA, Amgen provided its list of patents that could be asserted against Apotex. 42 U.S.C. § 262(l)(3)(A). On April 17, 2015, within 60 days of receiving Amgen's list of patents, Apotex provided Amgen with its invalidity and noninfringement contentions. 42 U.S.C. § 262(l)(3)(B). (On the same day, Apotex also provided a 180-day notice of commercial marketing although its biosimilar version of Neulasta had not yet been approved.) On June 16, 2015, within 60 days of receiving Apotex's contentions, Amgen provided Apotex with its contentions. 42 U.S.C. § 262(l)(3)(C). This completed the patent information exchanges of the BPCIA.

The parties then proceeded to determine which of the listed patents should be the subject of the first phase of BPCIA litigation (the so-called "immediate litigation phase"). The BPCIA does not prescribe an exact date after the completion of the patent information exchanges by which the parties need to begin negotiating the patents to be litigated immediately. But according to Amgen's complaint, Amgen and Apotex began to negotiate on June 22, 2015, about a week after Amgen served its infringement and validity contentions. The negotiations lasted fifteen days, until July 7, as set forth in the BPCIA. 42 U.S.C. § 262(l)(4). On July 7, Amgen and Apotex agreed that two patents should be the subject of an immediate patent infringement lawsuit. 42 U.S.C. § 262(l)(6)(A). Amgen then sued Apotex on August 6 in the Southern District of Florida, within the required 30 days of the parties agreeing on the patents to be litigated immediately. 42 U.S.C. § 262(l)(6)(A).

Amgen sued Apotex on two patents, a manufacturing patent and a patent covering Neulasta itself. The patent covering Neulasta issued in October of 1998 and is about to expire. The manufacturing patent, by contrast, issued just this year. In addition to patent infringement, Amgen sued Apotex for violating the BPCIA's notice of commercial marketing provision. According to the complaint, Apotex 1) provided its 180-day notice of commercial marketing long prior to any FDA approval, 2) has refused to provide a "legally effective Notice of Commercial pursuant to 42 U.S.C. § 262(l)(8)(A)" after approval by FDA, and 3) "intends to market its [proposed biosimilar] immediately upon receiving FDA approval." Amgen seeks an injunction preventing Apotex from marketing its product until at least 180 days after FDA approval, i.e., the first time that Apotex can provide an effective notice of commercial marketing under the Federal Circuit's interpretation of that provision in Amgen v. Sandoz.

Notably, Apotex's decision to comply with the patent dance came before the decision in Amgen and the court's interpretation of the information exchange provisions of the BPCIA as optional. Its notice of commercial marketing also preceded the decision and is legally ineffective under it. The panel's interpretation of the information exchange and notice of commercial marketing provisions, however, may not be the last word. Both Amgen and Sandoz have sought rehearing en banc. A number of biosimilar makers are also urging the full court to review the notice of commercial marketing provision and hold that the 180-day notice of commercial marketing can be provided at any point, even before regulatory approval, and that it does not need to be provided at all. Apotex has not weighed in on these issues.

Amgen's suit against Apotex has been set for trial in July 2016. But it is unclear when Apotex's proposed biosimilar of Neulasta will be approved, much less reach the market. Apotex's product is more complex than Sandoz's Zarxio, a biosimilar of Neupogen and the only biosimilar to have been approved by FDA. While Zarxio sailed through the regulatory process and received marketing approval by FDA's targeted 10-month decision date, Apotex's more complex product appears to be progressing more slowly. FDA has not announced plans for an advisory committee meeting for Apotex's product although the application was accepted for review in December 2014 and FDA's 10-month targeted decision date for the application is this October. Advisory committee meetings are targeted to occur in the eighth month of acceptance for review, but passed last month for Apotex's product without comment. In the meanwhile, one thing is clear; FDA's review of Apotex's product should provide important information on the requirements for biosimilarity for more complex biologics.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Patterson Belknap Webb & Tyler LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Patterson Belknap Webb & Tyler LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions